[Everolimus (Afinitor) for the treatment of renal cell carcinoma]
Comite d'Avaluacio de Medicaments d'Utilitzacio Hospitalaria (CAMUH)
Record ID 32010000704
Catalan
Authors' objectives:
To assess the efficacy, safety and efficiency of everolimus for the treatment of patients with advanced renal cell carcinoma, in whom the disease has progressed during or after treatment with a therapy targeting the VEGF.
Authors' recommendations:
Everolimus is a generally well-tolerated drug that has been proven to reduce the risk of progression in patients with clear cell RCC and good health status whose prior treatment with tyrosine kinase inhibitors has failed.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.gencat.cat/salut/depsan/units/aatrm/pdf/everolimus_carninoma_renal_aiaqs2011ca.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Sirolimus
Contact
Organisation Name:
Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address:
Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright:
Catalan Agency for Health Information, Assessment and Quality (CAHIAQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.